NasdaqGM:IVVDBiotechs
Why Invivyd (IVVD) Is Down 18.9% After Wider Q1 Loss And New Antibody Tolerability Data
Invivyd reported past Q1 2026 results showing revenue of US$13.74 million versus US$11.30 million a year earlier, alongside a wider net loss of US$41.40 million, and also registered a US$36.43 million common stock shelf for an ESOP-related offering.
Alongside these financial moves, Invivyd highlighted new research suggesting its COVID monoclonal antibody had markedly fewer early systemic reactions than common vaccine regimens, and outlined plans for the LIBERTY study to directly compare...